Analysts See $-0.13 EPS for Interpace Diagnostics Group, Inc. (IDXG)

March 15, 2018 - By Kurt Siggers

 Analysts See $ 0.13 EPS for Interpace Diagnostics Group, Inc. (IDXG)

Analysts expect Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) to report $-0.13 EPS on April, 4.They anticipate $3.38 EPS change or 104.00 % from last quarter’s $3.25 EPS. After having $-0.15 EPS previously, Interpace Diagnostics Group, Inc.’s analysts see -13.33 % EPS growth. The stock increased 1.91% or $0.02 during the last trading session, reaching $1.06. About 398,785 shares traded. Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) has declined 18.90% since March 15, 2017 and is downtrending. It has underperformed by 35.60% the S&P500.

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company has market cap of $28.46 million. The firm offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. It currently has negative earnings. The Company’s clients consist primarily of physicians, hospitals, and clinics.

More notable recent Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) news were published by: which released: “Interpace Diagnostics Announces Renewal and Extension of LabCorp National …” on August 28, 2017, also with their article: “Interpace Diagnostics Announces Increased Reimbursement for ThyGenX®” published on October 11, 2017, published: “Interpace Diagnostics Group Inc (IDXG) PT Lowered to $3 at Maxim Group” on February 14, 2018. More interesting news about Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) were released by: and their article: “Interpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung Assays” published on February 12, 2018 as well as‘s news article titled: “Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions …” with publication date: January 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: